{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:36:45Z","timestamp":1794433005362,"version":"4.9.1"},"reference-count":48,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We analyzed lymphocyte morphology, histology, immunophenotype, immunoglobulin heavy chain (IgVH) gene mutations, and clinical course in 80 unselected patients presenting with circulating t(11;14) lymphocytes. Of the 80 patients, 43 had peripheral lymphadenopathy (nodal group), and histology confirmed mantle cell lymphoma (MCL) in all. There were 37 patients with no lymphadenopathy (nonnodal group); 13 of 37 had histology, all showing MCL. IgVH genes were unmutated in 28 (90%) of 31 nodal and 15 (44%) of 34 nonnodal cases (P = .0001); CD38 was positive in 32 (94%) of 34 nodal and 16 (48%) of 33 nonnodal cases (P &amp;lt; .001); 41 (95%) of 43 nodal patients required immediate treatment compared with 18 (49%) of 37 nonnodal patients who had indolent disease (P &amp;lt; .0001). Median survival (95% confidence interval) was 30 months (10-50) in the nodal group and 79 months (22-136) in the nonnodal group (P = .005). Mutation status did not statistically affect survival, but of 6 long-term survivors (&amp;gt; 90 months) all were nonnodal and 5 of 5 had mutated IgVH genes. Lymphocyte morphology was heterogeneous in both groups: typical MCL in 56 cases (34 nodal, 22 nonnodal), blastoid MCL in 8 cases (3 nodal, 5 nonnodal), and small-cell MCL in 16 cases (6 nodal, 10 nonnodal, P = .12). Matutes immunophenotyping score was 1 in 65 cases and 2 in 15 (8 nodal, 7 nonnodal). We find no evidence against a diagnosis of MCL in the nonnodal group and suggest that mutated IgVH genes may help identify patients with indolent disease.<\/jats:p>","DOI":"10.1182\/blood-2002-06-1864","type":"journal-article","created":{"date-parts":[[2003,3,4]],"date-time":"2003-03-04T01:29:44Z","timestamp":1046741384000},"page":"4975-4981","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":257,"title":["A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease"],"prefix":"10.1182","volume":"101","author":[{"given":"Jenny","family":"Orchard","sequence":"first","affiliation":[{"name":"From the Department of Haematology, Royal Bournemouth Hospital, United Kingdom; Laboratory of Haematology, University Hospitals, Nantes, France; Tenovus Research Laboratory, University Hospitals, Southampton, United Kingdom; Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, London, United Kingdom; and Dorset Research and Development Support Unit, Poole Hospital, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Garand","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, Royal Bournemouth Hospital, United Kingdom; Laboratory of Haematology, University Hospitals, Nantes, France; Tenovus Research Laboratory, University Hospitals, Southampton, United Kingdom; Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, London, United Kingdom; and Dorset Research and Development Support Unit, Poole Hospital, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zadie","family":"Davis","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, Royal Bournemouth Hospital, United Kingdom; Laboratory of Haematology, University Hospitals, Nantes, France; Tenovus Research Laboratory, University Hospitals, Southampton, United Kingdom; Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, London, United Kingdom; and Dorset Research and Development Support Unit, Poole Hospital, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Babbage","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, Royal Bournemouth Hospital, United Kingdom; Laboratory of Haematology, University Hospitals, Nantes, France; Tenovus Research Laboratory, University Hospitals, Southampton, United Kingdom; Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, London, United Kingdom; and Dorset Research and Development Support Unit, Poole Hospital, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surinder","family":"Sahota","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, Royal Bournemouth Hospital, United Kingdom; Laboratory of Haematology, University Hospitals, Nantes, France; Tenovus Research Laboratory, University Hospitals, Southampton, United Kingdom; Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, London, United Kingdom; and Dorset Research and Development Support Unit, Poole Hospital, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estella","family":"Matutes","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, Royal Bournemouth Hospital, United Kingdom; Laboratory of Haematology, University Hospitals, Nantes, France; Tenovus Research Laboratory, University Hospitals, Southampton, United Kingdom; Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, London, United Kingdom; and Dorset Research and Development Support Unit, Poole Hospital, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Catovsky","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, Royal Bournemouth Hospital, United Kingdom; Laboratory of Haematology, University Hospitals, Nantes, France; Tenovus Research Laboratory, University Hospitals, Southampton, United Kingdom; Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, London, United Kingdom; and Dorset Research and Development Support Unit, Poole Hospital, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Thomas","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, Royal Bournemouth Hospital, United Kingdom; Laboratory of Haematology, University Hospitals, Nantes, France; Tenovus Research Laboratory, University Hospitals, Southampton, United Kingdom; Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, London, United Kingdom; and Dorset Research and Development Support Unit, Poole Hospital, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve\u0301","family":"Avet-Loiseau","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, Royal Bournemouth Hospital, United Kingdom; Laboratory of Haematology, University Hospitals, Nantes, France; Tenovus Research Laboratory, University Hospitals, Southampton, United Kingdom; Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, London, United Kingdom; and Dorset Research and Development Support Unit, Poole Hospital, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Oscier","sequence":"additional","affiliation":[{"name":"From the Department of Haematology, Royal Bournemouth Hospital, United Kingdom; Laboratory of Haematology, University Hospitals, Nantes, France; Tenovus Research Laboratory, University Hospitals, Southampton, United Kingdom; Academic Department of Haematology and Cytogenetics, Royal Marsden NHS Trust, London, United Kingdom; and Dorset Research and Development Support Unit, Poole Hospital, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021218225091600_REF1","doi-asserted-by":"crossref","unstructured":"Sola B, Roue G, Duquesne F, et al. Expression of cyclins D-type in B-chronic lymphoproliferative disorders. Leukemia.2000;14: 1318-1319.","DOI":"10.1038\/sj.leu.2401805"},{"key":"2020021218225091600_REF2","unstructured":"Avet-Loiseau H, Li JY, Facon T, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res.1998;58: 5640-5645."},{"key":"2020021218225091600_REF3","doi-asserted-by":"crossref","unstructured":"Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood.1996;88: 674-681.","DOI":"10.1182\/blood.V88.2.674.bloodjournal882674"},{"key":"2020021218225091600_REF4","doi-asserted-by":"crossref","unstructured":"Molina TJ, Delmer A, Cymbalista F, et al. Mantle cell lymphoma, in leukaemic phase with prominent splenomegaly: a report of eight cases with similar clinical presentation and aggressive outcome. Virchows Arch.2000;437: 591-598.","DOI":"10.1007\/s004280000284"},{"key":"2020021218225091600_REF5","doi-asserted-by":"crossref","unstructured":"Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood.1997;89: 2067-2078.","DOI":"10.1182\/blood.V89.6.2067"},{"key":"2020021218225091600_","doi-asserted-by":"crossref","unstructured":"Bosch F, Lopez-Guillermo A, Campo E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer.1998;82: 567-575.","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z"},{"key":"2020021218225091600_","doi-asserted-by":"crossref","unstructured":"Vandenberghe E, Wolf-Peeters C, Vaughan HG, et al. The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br J Haematol.1997;99: 842-847.","DOI":"10.1046\/j.1365-2141.1997.4693273.x"},{"key":"2020021218225091600_REF8","doi-asserted-by":"crossref","unstructured":"Weisenburger DD, Vose JM, Greiner TC, et al. Mantle cell lymphoma: a clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol.2000;64: 190-196.","DOI":"10.1002\/1096-8652(200007)64:3<190::AID-AJH9>3.0.CO;2-B"},{"key":"2020021218225091600_REF9","doi-asserted-by":"crossref","unstructured":"Matutes E, Carrara P, Coignet L, et al. FISH analysis for BCL-1 rearrangements and trisomy 12 helps the diagnosis of atypical B cell leukaemias. Leukemia.1999;13: 1721-1726.","DOI":"10.1038\/sj.leu.2401561"},{"key":"2020021218225091600_REF10","doi-asserted-by":"crossref","unstructured":"Singleton TP, Anderson MM, Ross CW, Schnitzer B. Leukemic phase of mantle cell lymphoma, blastoid variant. Am J Clin Pathol.1999;111: 495-500.","DOI":"10.1093\/ajcp\/111.4.495"},{"key":"2020021218225091600_","doi-asserted-by":"crossref","unstructured":"Viswanatha DS, Foucar K, Berry BR, Gascoyne RD, Evans HL, Leith CP. Blastic mantle cell leukemia: an unusual presentation of blastic mantle cell lymphoma. Mod Pathol.2000;13: 825-833.","DOI":"10.1038\/modpathol.3880144"},{"key":"2020021218225091600_REF12","doi-asserted-by":"crossref","unstructured":"Wong KF, Chan JK, So JC, Yu PH. Mantle cell lymphoma in leukemic phase: characterization of its broad cytologic spectrum with emphasis on the importance of distinction from other chronic lymphoproliferative disorders. Cancer.1999;86: 850-857.","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<850::AID-CNCR22>3.0.CO;2-Z"},{"key":"2020021218225091600_REF13","doi-asserted-by":"crossref","unstructured":"Brito-Babapulle V, Ellis J, Matutes E, et al. Translocation t(11;14)(q13;q32) in chronic lymphoid disorders. Genes Chromosomes Cancer.1992;5: 158-165.","DOI":"10.1002\/gcc.2870050210"},{"key":"2020021218225091600_","doi-asserted-by":"crossref","unstructured":"Cuneo A, Balboni M, Piva N, et al. Atypical chronic lymphocytic leukaemia with t(11;14)(q13; q32): karyotype evolution and prolymphocytic transformation. Br J Haematol.1995;90: 409-416.","DOI":"10.1111\/j.1365-2141.1995.tb05167.x"},{"key":"2020021218225091600_","doi-asserted-by":"crossref","unstructured":"Troussard X, Mauvieux L, Radford-Weiss I, et al. Genetic analysis of splenic lymphoma with villous lymphocytes: a Groupe Francais d'Hematologie Cellulaire (GFHC) study. Br J Haematol.1998;101: 712-721.","DOI":"10.1046\/j.1365-2141.1998.00764.x"},{"key":"2020021218225091600_","doi-asserted-by":"crossref","unstructured":"Levy V, Ugo V, Delmer A, et al. Cyclin D1 overexpression allows identification of an aggressive subset of leukemic lymphoproliferative disorder. Leukemia.1999;13: 1343-1351.","DOI":"10.1038\/sj.leu.2401470"},{"key":"2020021218225091600_REF17","doi-asserted-by":"crossref","unstructured":"Schlette E, Bueso-Ramos C, Giles F, Glassman A, Hayes K, Medeiros LJ. Mature B-cell leukemias with more than 55% prolymphocytes: a heterogeneous group that includes an unusual variant of mantle cell lymphoma. Am J Clin Pathol.2001;115: 571-581.","DOI":"10.1309\/PPK0-TJUK-1UAR-3194"},{"key":"2020021218225091600_REF18","doi-asserted-by":"crossref","unstructured":"Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood.1999;94: 1840-1847.","DOI":"10.1182\/blood.V94.6.1840"},{"key":"2020021218225091600_REF19","doi-asserted-by":"crossref","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood.1999;94: 1848-1854.","DOI":"10.1182\/blood.V94.6.1848"},{"key":"2020021218225091600_REF20","doi-asserted-by":"crossref","unstructured":"Algara P, Mateo MS, Sanchez-Beato M, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood.2002;99: 1299-1304.","DOI":"10.1182\/blood.V99.4.1299"},{"key":"2020021218225091600_REF21","doi-asserted-by":"crossref","unstructured":"Hummel M, Tamaru J, Kalvelage B, Stein H. Mantle cell (previously centrocytic) lymphomas express VH genes with no or very little somatic mutations like the physiologic cells of the follicle mantle. Blood.1994;84: 403-407.","DOI":"10.1182\/blood.V84.2.403.403"},{"key":"2020021218225091600_REF22","doi-asserted-by":"crossref","unstructured":"Andersen NS, Donovan JW, Borus JS, et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood.1997;90: 4212-4221.","DOI":"10.1182\/blood.V90.10.4212"},{"key":"2020021218225091600_","doi-asserted-by":"crossref","unstructured":"Du MQ, Diss TC, Xu CF, Wotherspoon AC, Isaacson PG, Pan LX. Ongoing immunoglobulin gene mutations in mantle cell lymphomas. Br J Haematol.1997;96: 124-131.","DOI":"10.1046\/j.1365-2141.1997.8712503.x"},{"key":"2020021218225091600_","doi-asserted-by":"crossref","unstructured":"Laszlo T, Nagy M, Kelenyi G, Matolcsy A. Immunoglobulin V(H) gene mutational analysis suggests that blastic variant of mantle cell lymphoma derives from different stages of B-cell maturation. Leuk Res.2000;24: 27-31.","DOI":"10.1016\/S0145-2126(99)00156-3"},{"key":"2020021218225091600_REF25","doi-asserted-by":"crossref","unstructured":"Pittaluga S, Tierens A, Pinyol M, Campo E, Delabie J, Wolf-Peeters C. Blastic variant of mantle cell lymphoma shows a heterogenous pattern of somatic mutations of the rearranged immunoglobulin heavy chain variable genes. Br J Haematol.1998;102: 1301-1306.","DOI":"10.1046\/j.1365-2141.1998.00907.x"},{"key":"2020021218225091600_REF26","doi-asserted-by":"crossref","unstructured":"Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias: French-American-British (FAB) Cooperative Group. J Clin Pathol.1989;42: 567-584.","DOI":"10.1136\/jcp.42.6.567"},{"key":"2020021218225091600_REF27","doi-asserted-by":"crossref","unstructured":"Ott G, Kalla J, Ott MM, et al. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood.1997;89: 1421-1429.","DOI":"10.1182\/blood.V89.4.1421"},{"key":"2020021218225091600_REF28","doi-asserted-by":"crossref","unstructured":"Moreau EJ, Matutes E, A'Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol.1997;108: 378-382.","DOI":"10.1093\/ajcp\/108.4.378"},{"key":"2020021218225091600_REF29","unstructured":"Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia.1994;8: 1640-1645."},{"key":"2020021218225091600_REF30","doi-asserted-by":"crossref","unstructured":"Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood.2002;99: 1023-1029.","DOI":"10.1182\/blood.V99.3.1023"},{"key":"2020021218225091600_REF31","doi-asserted-by":"crossref","unstructured":"Zhu D, Hawkins RE, Hamblin TJ, Stevenson FK. Clonal history of a human follicular lymphoma as revealed in the immunoglobulin variable region genes. Br J Haematol.1994;86: 505-512.","DOI":"10.1111\/j.1365-2141.1994.tb04780.x"},{"key":"2020021218225091600_REF32","doi-asserted-by":"crossref","unstructured":"Brezinschek HP, Brezinschek RI, Lipsky PE. Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. J Immunol.1995;155: 190-202.","DOI":"10.4049\/jimmunol.155.1.190"},{"key":"2020021218225091600_REF33","unstructured":"Bea S, Ribas M, Hernandez JM, et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood.1999;93: 4365-4374."},{"key":"2020021218225091600_REF34","doi-asserted-by":"crossref","unstructured":"Bentz M, Plesch A, Bullinger L, et al. t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer.2000;27: 285-294.","DOI":"10.1002\/(SICI)1098-2264(200003)27:3<285::AID-GCC9>3.0.CO;2-M"},{"key":"2020021218225091600_REF35","doi-asserted-by":"crossref","unstructured":"Cuneo A, Bigoni R, Rigolin GM, et al. Cytogenetic profile of lymphoma of follicle mantle lineage: correlation with clinicobiologic features. Blood.1999;93: 1372-1380.","DOI":"10.1182\/blood.V93.4.1372"},{"key":"2020021218225091600_REF36","doi-asserted-by":"crossref","unstructured":"Geissmann F, Ruskone-Fourmestraux A, Hermine O, et al. Homing receptor alpha4beta7 integrin expression predicts digestive tract involvement in mantle cell lymphoma. Am J Pathol.1998;153: 1701-1705.","DOI":"10.1016\/S0002-9440(10)65684-2"},{"key":"2020021218225091600_REF37","doi-asserted-by":"crossref","unstructured":"Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood.2000;95: 627-632.","DOI":"10.1182\/blood.V95.2.627"},{"key":"2020021218225091600_REF38","doi-asserted-by":"crossref","unstructured":"Cohen PL, Kurtin PJ, Donovan KA, Hanson CA. Bone marrow and peripheral blood involvement in mantle cell lymphoma. Br J Haematol.1998;101: 302-310.","DOI":"10.1046\/j.1365-2141.1998.00684.x"},{"key":"2020021218225091600_REF39","doi-asserted-by":"crossref","unstructured":"Wasman J, Rosenthal NS, Farhi DC. Mantle cell lymphoma: morphologic findings in bone marrow involvement. Am J Clin Pathol.1996;106: 196-200.","DOI":"10.1093\/ajcp\/106.2.196"},{"key":"2020021218225091600_REF40","unstructured":"Savilo E, Campo E, Mollejo M, et al. Absence of cyclin D1 protein expression in splenic marginal zone lymphoma. Mod Pathol.1998;11: 601-606."},{"key":"2020021218225091600_REF41","doi-asserted-by":"crossref","unstructured":"Deneys V, Michaux L, Leveugle P, et al. Atypical lymphocytic leukemia and mantle cell lymphoma immunologically very close: flow cytometric distinction by the use of CD20 and CD54 expression. Leukemia.2001;15: 1458-1465.","DOI":"10.1038\/sj.leu.2402200"},{"key":"2020021218225091600_REF42","doi-asserted-by":"crossref","unstructured":"Bigoni R, Cuneo A, Milani R, et al. Secondary chromosome changes in mantle cell lymphoma: cytogenetic and fluorescence in situ hybridization studies. Leuk Lymphoma.2001;40: 581-590.","DOI":"10.3109\/10428190109097656"},{"key":"2020021218225091600_REF43","doi-asserted-by":"crossref","unstructured":"Martinez-Climent JA, Vizcarra E, Sanchez D, et al. Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. Blood.2001;98: 3479-3482.","DOI":"10.1182\/blood.V98.12.3479"},{"key":"2020021218225091600_REF44","unstructured":"Welzel N, Le T, Marculescu R, et al. Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res.2001;61: 1629-1636."},{"key":"2020021218225091600_REF45","doi-asserted-by":"crossref","unstructured":"Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med.2001;194: 1625-1638.","DOI":"10.1084\/jem.194.11.1625"},{"key":"2020021218225091600_REF46","doi-asserted-by":"crossref","unstructured":"Camacho FI, Algara P, Rodriguez A, et al. Molecular heterogeneity in MCL, defined by the use of specific VH genes and the frequency of somatic mutations. Blood. Prepublished on January 2, 2003 as DOI 10.1182\/blood-2002-11-3456.","DOI":"10.1182\/blood-2002-11-3456"},{"key":"2020021218225091600_REF47","unstructured":"Kienle D, Kroeber A, Leupol E, et al. VH mutation status and gene usage in mantle cell lymphoma; correlation with genomic aberrations and survival [abstract]. Blood.2002;100: 90a."},{"key":"2020021218225091600_REF48","doi-asserted-by":"crossref","unstructured":"Thorselius M, Walsh S, Eriksson I, et al. Somatic hypermutation and V(H) gene usage in mantle cell lymphoma. Eur J Haematol.2002;68: 217-224.","DOI":"10.1034\/j.1600-0609.2002.01662.x"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/12\/4975\/1687437\/h81203004975.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/12\/4975\/1687437\/h81203004975.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T21:19:08Z","timestamp":1682457548000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/12\/4975\/17000\/A-subset-of-t1114-lymphoma-with-mantle-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6,15]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,6,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-06-1864","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6,15]]}}}